‘Global Pharma Contract Sales Market Worth $8.09bn In 2021’ Says Visiongain Report

17 August 2018
Pharma

Visiongain’s new report Global Pharma Contract Sales Market 2017-2027: Contract Detailing, Contract Non-Personal Promotion, Medical Education Services, Sample Management Services, Teledetailing Services, Edetailing Services indicates that the global pharma contract sales market will see $8.09bn in spending in 2021.

The global pharma contract sales market is expected to grow at a CAGR of 10.5% in the first half of the forecast period. The market is expected to grow at a CAGR of 9.5% from 2016-2027. The market is estimated at $4.9bn in 2016 and $8.09bn in 2021.
The lead analyst of the report said: “Pharma companies will increasingly look to outsource field sales to CSOs, for a wide range of reasons including for promotion for mature products with smaller marketing budgets, for product launches for smaller pharma companies, and for expertise in reaching emerging markets.
Demand for MSLs and clinical education teams has risen rapidly in recent years, driven by the launch of complex, specialty medicines for chronic diseases, as well as by increased awareness of treatment options, and choice, among patients and doctors. Outsourcing to CSOs accounted for between 10% and 20% of personal promotional spending in the leading developed markets in 2016. The rising trend in outsourcing across the whole pharma sector will benefit the contract sales market in this 10-year forecast period, as will challenges in market access, complex drug development and the increasing influence of the payer in prescribing decisions.”
The 260-page report contains 95 tables and 65 figures that add visual analysis in order to explain the developing trends within the Global Pharma Contract Sales Market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments: Contract detailing (personal promotion/field sales), Contract non-personal promotion, with further sub-forecasting for teledetailing, eDetailing and others, Medical education services and Sample management services
This report also breaks down the revenue forecast for pharma contract sales market by therapeutic segments: Cardiovascular disease, Metabolic disorders, Cancer treatment and Other.

The 260-page report offers market forecasts for the US, Germany, UK, France, Italy, Spain, China, Japan, India, Russia, Brazil and Rest of the World. Moreover, our work discusses the leading companies in pharma contract sales.

The report Global Pharma Contract Sales Market 2017-2027: Contract Detailing, Contract Non-Personal Promotion, Medical Education Services, Sample Management Services, Teledetailing Services, Edetailing Services report will be of value to anyone who wants to better understand the pharma contract sales market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the pharma contract sales market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Acute Myeloid Leukaemia market set to grow to $2.8bn by 2022” says new Visiongain report

Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults and among the most lethal. In the United States, the annual incidence of AML is 19 000 new cases, and the incidence of AML-associated deaths is 10 000.

21 September 2018

Read

“Cell-Based Assay market set to grow to $22bn by 2022” says new Visiongain report

Cell-based assays hold a number of advantages over traditional biochemical assays and animal models, and these advantages have driven the increased demand for these assays in recent years.

18 September 2018

Read

Non-Small Cell Lung Cancer (NSCLC) Drugs Market To Be Worth $8.8bn In 2019, A New Visiongain Analysis Predicts

That investigation gives revenue predictions to 2025 at overall world market, submarket, product and national level.

14 September 2018

Read

The Cholesterol-Lowering Drugs Market Will Reach $24.63bn In 2019 Predicts New Visiongain Report

Recent financial performance is analysed, along with a breakdown of each company’s leading products and an analysis of news that may influence the course of the company.

14 September 2018

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1